AAP
BIO icon

Ardsley Advisory Partners’s Bio-Rad Laboratories Class A BIO Stock Holding History

Ardsley Advisory Partners’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-2,000
Closed -$665K – 153
2019
Q3 		$665K Buy
+2,000
New +$652K 0.15% 79
2014
Q2 		– Sell
-3,000
Closed -$384K – 250
2014
Q1 		$384K Buy
+3,000
New +$385K 0.06% 158

Other funds holding BIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Ardsley Advisory Partners's BIO Position: Q4 2019 in Review

Ardsley Advisory Partners sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2019, closing a stake of 2,000 shares — an estimated $665K sold.

Ardsley Advisory Partners first reported a position in BIO in Q1 2014 and held it in 2 quarters. The position peaked at $665K in Q3 2019. 386 funds tracked by Wall St. Rank hold BIO as of Q4 2019.

  • Ardsley Advisory Partners reported no remaining Bio-Rad Laboratories Class A position as of Q4 2019 after selling out during the quarter.
  • Ardsley Advisory Partners sold 2,000 Bio-Rad Laboratories Class A shares in Q4 2019, an estimated $665K.
  • Ardsley Advisory Partners first reported a position in Bio-Rad Laboratories Class A in Q1 2014 and held it in 2 quarters.
  • Ardsley Advisory Partners's Bio-Rad Laboratories Class A position peaked at $665K in Q3 2019.
  • 386 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2019.

Based on Ardsley Advisory Partners's 13F filing for Q4 2019, filed 14 Feb 2020.